首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >ANTIBODY-TARGETED SUPERANTIGENS ARE POTENT INDUCERS OF TUMOR-INFILTRATING T LYMPHOCYTES IN VIVO
【24h】

ANTIBODY-TARGETED SUPERANTIGENS ARE POTENT INDUCERS OF TUMOR-INFILTRATING T LYMPHOCYTES IN VIVO

机译:靶向抗体的上位药是体内肿瘤浸润性T淋巴细胞的强诱导剂

获取原文
获取原文并翻译 | 示例
           

摘要

Recruitment of antigen-specific tumor-infiltrating lymphocytes (TILs) is a major goal for immunotherapy of malignant tumors. We now describe that T-cell-activating superantigens targeted to a tumor by monoclonal antibodies induced large numbers of pseudospecific TILs and eradication of micrometastases, As a model for tumor micrometastases, syngeneic B16 melanoma cells transfected with the human colon carcinoma antigen C215 were injected intravenously into C57BL/6 mice and therapy with an anti-C215 Fab fragment-staphylococcal enterotoxin A (C215Fab-SEA) fusion protein reacting with the C215 antigen was initiated when visible lung metastases were established, More than 90% reduction of the number of lung metastases was observed when mice carrying 5-day-old established lung metastases were treated with C215Fab-SEA. The antitumor effect of C215Fab-SEA was shown to be T-cell-dependent since no therapeutic effect was seen in T-cell-deficient nude mice, Depletion of T-cell subsets by injection of monoclonal antibody demonstrated that CD8(+) cells were the most prominent effector cells although some contribution from CD4(+) cells was also noted. C215Fab-SEA treatment induced massive tumor infiltration of CD4(+) and CD8(+) T cells, while only scattered T cells were observed in untreated tumors, SEA treatment alone induced a slight general inflammatory response in the lung parenchyme, but no specific accumulation of T cells was seen in the tumor. TILs induced by C215Fab-SEA were mainly CD8(+) but a substantial number of CD4(+) cells were also present, Immunohistochemical analysis showed strong production of the tumorcidal cytokines tumor necrosis factor alpha and interferon gamma in the tumor, Thus, the C215Fab-SEA fusion protein targets effector T lymphocytes to established tumors in vivo and provokes a strong local antitumor immune response. [References: 16]
机译:抗原特异性肿瘤浸润淋巴细胞(TIL)的招募是恶性肿瘤免疫治疗的主要目标。现在我们描述通过单克隆抗体靶向肿瘤的T细胞活化超抗原诱导大量的假特异性TILs和根除微转移。作为肿瘤微转移的模型,用人结肠癌抗原C215转染的同基因B16黑素瘤细胞被静脉内注射。建立C57BL / 6小鼠并用抗C215 Fab片段-葡萄球菌肠毒素A(C215Fab-SEA)融合蛋白进行治疗,当可见的肺转移建立后,与C215抗原起反应,肺转移数量减少90%以上当用C215Fab-SEA处理携带5天大的已建立的肺转移的小鼠时,观察到这种现象。 C215Fab-SEA的抗肿瘤作用显示为T细胞依赖性的,因为在缺乏T细胞的裸鼠中未观察到治疗作用。通过注射单克隆抗体清除T细胞亚群表明,CD8(+)细胞是尽管也注意到了CD4(+)细胞的一些贡献,但最显着的效应细胞。 C215Fab-SEA治疗可诱导CD4(+)和CD8(+)T细胞大量浸润,而未治疗的肿瘤中仅观察到散在的T细胞,仅SEA治疗可在肺实质中引起轻微的一般炎症反应,但没有特异性积累在肿瘤中观察到T细胞的数目。 C215Fab-SEA诱导的TIL主要是CD8(+),但也存在大量CD4(+)细胞,免疫组织化学分析显示,肿瘤中有杀伤性细胞因子,肿瘤坏死因子α和干扰素γ的大量产生,因此,C215Fab -SEA融合蛋白将效应T淋巴细胞靶向体内已建立的肿瘤,并引起强烈的局部抗肿瘤免疫反应。 [参考:16]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号